Search the GHTC website

Global health R&D delivers for Washington

US government investment in global health R&D has delivered

$3 billion
to Washington research institutions
37,500+ new jobs
for Washington
Washington's top USG-funded global health R&D institutions

Washington's top USG-funded global health R&D institutions

Fred Hutchinson Cancer Research Center (including the HIV Vaccine Trials Network)
$1.8 billion
University of Washington (including Harborview Medical Center)
$468 million
Seattle Children's Hospital (including Seattle Children's Research Institute and Center for Global Infectious Disease Research)
$359.6 million
Access to Advanced Health Institute (AAHI) (formerly Infectious Disease Research Institute)
$85.5 million
PATH (including Meningitis Vaccine Project and Malaria Vaccine Initiative)
$64.3 million
Benaroya Research Institute at Virginia Mason
$45.8 million
The Geneva Foundation
$28.5 million
$20 million
PAI Life Sciences (formerly Protein Advances Inc.)
$19 million
Institute for Systems Biology
$18.7 million
InBios International Inc.
$16 million
Washington State University
$12.8 million
$10 million
Pacific Northwest National Laboratory
$5.4 million
$4.6 million
Group Health Cooperative*
$4.6 million
Orlance Inc.
$2.7 million
Scisco Genetics Inc.
$2.6 million
Lumen Bioscience
$2.2 million
SpringStar Inc.*
$1.2 million
Tasso Inc.
$1.2 million
TRIA Bioscience Corp.*
$793 thousand
Allen Institute
$778 thousand
Phage Diagnostics
$736 thousand
Syntrix Biosystems
$710 thousand
Gonzaga University
$622 thousand
$612 thousand
$487 thousand
Lamprogen Inc.
$464 thousand
Central Washington University
$446 thousand
ID Genomics
$323 thousand
Nortis Bio
$289 thousand
Cyrus Biotechnology (including Orthogonal Biologics)
$277 thousand
$272 thousand
Maren-Go Solutions Corporation
$54 thousand
Emerald Biostructures*
$26 thousand

Washington's top areas of global health R&D by USG funding

Neglected tropical diseases
Buruli ulcer
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Global health R&D at work in Washington

Several million babies born each year in Africa and Asia cannot breastfeed due to prematurity or cleft lip or palate. Tools such as breast pumps and bottles are impractical and unhygienic in settings that lack clean water and electricity. To help save these infants from starving, the University of Washington, Seattle Children’s Hospital, and PATH developed the NIFTY cup, a soft, silicone bowl with a tiny reservoir that allows these infants to lap up lifesaving breast milk. Since 1996, more than 80,000 cups have been distributed in more than 40 countries worldwide.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Patrick McKern